论文部分内容阅读
目的探讨自体造血干细胞移植治疗淋巴瘤的临床疗效及安全性。方法回顾性分析2004年1月至2014年12月自体造血干细胞移植治疗淋巴瘤56例及随访结果。结果随访中位时间49个月。目前存活22例。余34例死亡原因分别为:复发28例,单次移植者24例,双次移植者4例;移植相关死亡6例,单次移植者3例,双次移植者3例。结论自体造血干细胞移植可以改善淋巴瘤患者尤其是恶性程度较高患者的预后;双次自体造血干细胞移植复发率低于单次移植,可能会增加移植相关死亡。
Objective To investigate the clinical efficacy and safety of autologous hematopoietic stem cell transplantation in the treatment of lymphoma. Methods A retrospective analysis of 56 cases of lymphoma treated with autologous hematopoietic stem cell transplantation from January 2004 to December 2014 and the follow-up results were retrospectively analyzed. The median follow-up time was 49 months. Currently 22 cases survive. The remaining 34 cases of death were as follows: 28 cases of recurrence, 24 cases of single transplants, 4 cases of double transplants; transplant-related death in 6 cases, single transplanted in 3 cases, double transplanted in 3 cases. Conclusion Autologous hematopoietic stem cell transplantation can improve the prognosis of patients with lymphoma, especially in patients with higher malignancy. The recurrence rate of double autologous hematopoietic stem cell transplantation is lower than that of single transplantation, which may increase the graft-related death.